Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.
- Conditions
- the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients
- Registration Number
- NCT05008016
- Lead Sponsor
- Mohammed VI University Hospital
- Brief Summary
Background:
Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection .
Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .
- Detailed Description
Our objective is to assess the relationship between Procalcitonin and 30-day mortality in patients admitted to the resuscitation department of the Mohammed VI University Hospital Center, Oujda, Morocco, infected by the SARS COV 2 Virus .
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 582
- Clinical diagnosis of SARS COV2 infection needed admission in ICU .
- patient under 15 ans
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Procalcitonin is a marker of mortality through study completion, an average of 8 mounths as a cutoff 0.5 ng/ml Procalcitonin could be used as mortality factors
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
younes Oujidi
🇲🇦Berkane, Morocco